|
A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies. |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Survivornet; TeneoBio |
Consulting or Advisory Role - Merck |
|
|
|
Honoraria - AstraZeneca; Cancer Expert Now; Clovis Oncology; Eisai; Xodus Medical |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology |
|
Research Funding - AstraZeneca Canada |
Travel, Accommodations, Expenses - Eisai |
|
|
|
Stock and Other Ownership Interests - Nurix |
Patents, Royalties, Other Intellectual Property - Compugen Inc, Nurix Therapeutics |
|
|
|
Stock and Other Ownership Interests - Allogene Therapeutics; Biomarin; Crispr Therapeutics; Novocure; Seagen |
|
|
|
Stock and Other Ownership Interests - Nurix |
Travel, Accommodations, Expenses - Nurix |
|
|
|
Stock and Other Ownership Interests - Principa Biopharma |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Nurix |
Consulting or Advisory Role - Clinigen Group |
|
|
Employment - Allogene Therapeutics; Nurix |
Stock and Other Ownership Interests - Allogene Therapeutics; Nurix |
|
|
Stock and Other Ownership Interests - Ovation Diagnostics |
Honoraria - Seagen; Tesaro |
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Genentech; GlaxoSmithKline; Legend Biotech; Merck; Mersana; Regeneron; Seattle Genetics/Astellas; Tesaro |
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro |
Research Funding - Anixa Biosciences (Inst); Merck (Inst); Prescient Therapeutics (Inst) |
Travel, Accommodations, Expenses - TapImmune Inc. |
Other Relationship - AstraZeneca; GlaxoSmithKline/Tesaro |